Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 466-472

  Matalon, Shay ^a   Rasmussen, Thomas A ^b   Dinarello, Charles A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BELINOSTAT; BUTYRIC ACID; CG 05; CG 06; ENFUVIRTIDE; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; OXAMFLATIN; RALTEGRAVIR; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DISEASE CARRIER; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; ERADICATION THERAPY; EX VIVO STUDY; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTONE ACETYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; JUVENILE RHEUMATOID ARTHRITIS; LATENT VIRUS INFECTION; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS EXPRESSION; VIRUS GENE;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXAMIC ACIDS;

EID: 79957934393     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00076     Document Type: Article

References (64)

1. Imamichi H, et al. (2001) Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretrovi-ral therapy are similar to the viral quasi species present before initiation of therapy. J. Infect. Dis. 183:36-50.
2. Zhang L, et al. (2000) Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Invest. 106:839-45.
3. Davey RT Jr, et al. (1999) HIV-1 and T cell dynamics after interruption of highly active anti-retroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. U.S.A. 96:15109-14.
4. Chun TW, et al. (2000) Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757-61.
5. Chun TW, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 387:183-8.
6. Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretrovi-ral therapy. Science. 278:1295-300.
7. Chun TW, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 95:8869-73.
8. Lori F, et al. (1999) Treatment of human immunodeficiency virus infection with hydroxyurea, di-danosine, and a protease inhibitor before serocon-version is associated with normalized immune parameters and limited viral reservoir. J. Infect. Dis. 180:1827-32.
9. Siliciano JD, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-8.
10. Zhang L, et al. (1999) Quantifying residual HIV-1 replication in patients receiving combination an-tiretroviral therapy. N. Engl. J. Med. 340:1605-13.
11. Ramratnam B, et al. (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6:82-5.
12. Chun TW, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115:3250-5.
13. Ramratnam B, et al. (2004) Intensification of anti-retroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J. Acquir. Immune Defic. Syndr. 35:33-7.
14. Chun TW, et al. (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195:1762-4.
15. van Praag RM, et al. (2001) OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin. Immunol. 21:218-26.
16. Prins JM, et al. (1999) Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. Aids. 13:2405-10.
17. Dybul M, et al. (2002) Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J. Infect. Dis. 185:61-8.
18. Bowman MC, Archin NM, Margolis DM. (2009) Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev. Mol. Med. 11:e6.
19. Tran TA, et al. (2008) Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One. 3:e3305.
20. Thornton AM, Shevach EM. (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting inter-leukin 2 production. J. Exp. Med. 188:287-96.
21. Stellbrink HJ, et al. (2002) Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). Aids. 16:1479-87.
22. Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562-73.
23. Wang L, de Zoeten EF, Greene MI, Hancock WW. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug. Discov. 8:969-81.
24. Verdin E, Paras P, Van Lint C. (1993) Chro-matin disruption in the promoter of human immunodeficiency virus type 1 during transcrip-tional activation. EMBO J. 12:3249-3259.
25. Williams SA, et al. (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-49.
26. Keedy KS, et al. (2009) A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J. Virol. 83:4749-56.
27. Coull JJ, et al. (2000) The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of hi-stone deacetylase 1. J. Virol. 74:6790-9.
28. Hsia SC, Shi YB. (2002) Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor. Mol. Cell. Biol. 22:4043-52.
29. Jiang G, Espeseth A, Hazuda DJ, Margolis DM. (2007) c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J. Virol. 81:10914-23.
30. Tyagi M, Karn J. (2007) CBF-1 promotes tran-scriptional silencing during the establishment of HIV-1 latency. EMBO J. 26:4985-95.
31. Imai K, Okamoto T. (2006) Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J. Biol. Chem. 281:12495-505.
32. Lusic M, Marcello A, Cereseto A, Giacca M. (2003) Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J. 22:6550-61.
33. Thierry S, et al. (2004) Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acety-lation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. J. Virol. 78:12198-206.
34. Lehrman G, et al. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 366:549-55.
35. Siliciano JD, et al. (2007) Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J. Infect. Dis. 195:833-36.
36. Sagot-Lerolle N, et al. (2008) Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Aids. 22:1125-9.
37. Archin NM, et al. (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. Aids. 22:1131-5.
38. Archin NM, et al. (2010) Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 5:e9390.
39. Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and mono-cytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1-9.
40. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. (2007) FDA approval summary: vorino- stat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12:1247-52.
41. Archin NM, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoy-lanilide hydroxamic acid. AIDS Res. Hum. Retro-viruses. 25:207-12.
42. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP. (2009) Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res. Hum. Retro-viruses. 25:883-7.
43. Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353-362.
44. Vojinovic J, Damjanov N. (2011) HDAC inhibition in rheumatoid arthritis and juvenile idio-pathic arthritis. Mol. Med. 17:397-403.
45. Khan N, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409:581-9.
46. Gimsing P, et al. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 81:170-6.
47. Mackay HJ, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur. J. Cancer. 46:1573-9.
48. Archin NM, et al. (2009) Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. Aids. 23:1799-806.
49. Valenzuela-Fernandez A, et al. (2005) Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol. Biol. Cell 16:5445-54.
50. Morselli PL, Franco-Morselli R. (1980) Clinical pharmacokinetics of antiepileptic drugs in adults. Pharmacol. Ther. 10:65-101.
51. Kuller LH, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5:e203.
52. Baker J V, et al. (2011) Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretrovi-ral therapy in patients with HIV infection. J. Ac-quir. Immune Defic. Syndr. 56:36-43.
53. Laughlin MA, et al. (1993) Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Vi r o l -ogy. 196:496-505.
54. Van Lint C, Emiliani S, Ott M, Verdin E. (1996) Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to his-tone acetylation. EMBO J. 15:1112-20.
55. Witvrouw M, et al. (1997) Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res. Hum. Retroviruses. 13:187-92.
56. El Kharroubi A, Piras G, Zensen R, Martin MA. (1998) Transcriptional activation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol. Cell. Biol. 18:2535-44.
57. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. Aids. 18:1101-8.
58. Contreras X, et al. (2009) Suberoylanilide hydrox-amic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284:6782-9.
59. Savarino A, et al. (2009) Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology. 6:52.
60. Reuse S, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One. 4:e6093.
61. Shehu-Xhilaga M, et al. (2009) The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. Aids. 23:2047-50.
62. Choi BS, et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. Aids. 24:609-11.
63. Yin H, Zhang Y, Zhou X, Zhu H. (2010) His-tonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol. Biol. Rep. 2010, Dec 23 [Epub ahead of print].
64. Colin L, Van Lint C. (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 6: 111.